Last reviewed · How we verify
OnabotulinumtoxinA X
At a glance
| Generic name | OnabotulinumtoxinA X |
|---|---|
| Also known as | OnabotA X |
| Sponsor | Allergan |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines (PHASE2)
- A Study To Assess the Adverse Effects and Change in Condition of OnabotulinumtoxinA X Injection in Adult Participants With Forehead Lines (PHASE2)
- A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines (PHASE2)
- Treatment of Gastrocnemius Tightness and Subsequent Chronic Plantar Fasciitis with Botulinum Toxin a
- Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome (PHASE2)
- A Safety and Efficacy Study of Different Injections Volumes of Botulinum Toxin Type A, Azzalure, in the Glabellar Lines (PHASE4)
- Botulinum Toxin A as Treatment for Chronic Postsurgical Pain Following Lung Cancer Surgery (PHASE1, PHASE2)
- Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OnabotulinumtoxinA X CI brief — competitive landscape report
- OnabotulinumtoxinA X updates RSS · CI watch RSS
- Allergan portfolio CI